Daniel E. Levy

1.3k total citations
32 papers, 1.0k citations indexed

About

Daniel E. Levy is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Daniel E. Levy has authored 32 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 15 papers in Organic Chemistry and 5 papers in Oncology. Recurrent topics in Daniel E. Levy's work include Carbohydrate Chemistry and Synthesis (6 papers), Synthesis and biological activity (5 papers) and Glycosylation and Glycoproteins Research (4 papers). Daniel E. Levy is often cited by papers focused on Carbohydrate Chemistry and Synthesis (6 papers), Synthesis and biological activity (5 papers) and Glycosylation and Glycoproteins Research (4 papers). Daniel E. Levy collaborates with scholars based in United States, Canada and Japan. Daniel E. Levy's co-authors include Péter Fügedi, F. Plum, J. B. Brierley, Ranga Robinson, Bradley H. Strauss, Robert M. Scarborough, James Tomlinson, Robert J. Chisholm, Alan M. Ezrin and Richard A. Logan and has published in prestigious journals such as Journal of Biological Chemistry, Journal of the American College of Cardiology and Circulation Research.

In The Last Decade

Daniel E. Levy

31 papers receiving 971 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel E. Levy United States 14 516 292 181 133 122 32 1.0k
Alexander S. Antonov Russia 21 493 1.0× 212 0.7× 147 0.8× 173 1.3× 83 0.7× 73 1.5k
Sonia Lamontagne Canada 19 525 1.0× 314 1.1× 163 0.9× 64 0.5× 191 1.6× 22 1.3k
Robert A. Galemmo United States 19 494 1.0× 262 0.9× 96 0.5× 90 0.7× 158 1.3× 46 1.0k
Christopher R. Smith United Kingdom 23 832 1.6× 161 0.6× 241 1.3× 77 0.6× 374 3.1× 62 1.7k
Diane A. Trainor United States 17 529 1.0× 252 0.9× 88 0.5× 50 0.4× 175 1.4× 22 1.0k
Karl F. Erhard United States 22 772 1.5× 262 0.9× 100 0.6× 41 0.3× 205 1.7× 43 1.4k
Thais M. Sielecki United States 18 378 0.7× 420 1.4× 52 0.3× 67 0.5× 280 2.3× 26 1.1k
John Wityak United States 24 554 1.1× 581 2.0× 46 0.3× 73 0.5× 179 1.5× 46 1.4k
Patricia Kraft United States 19 529 1.0× 168 0.6× 114 0.6× 159 1.2× 116 1.0× 50 971
Bernd Riedl Germany 20 684 1.3× 482 1.7× 46 0.3× 67 0.5× 148 1.2× 42 1.2k

Countries citing papers authored by Daniel E. Levy

Since Specialization
Citations

This map shows the geographic impact of Daniel E. Levy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel E. Levy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel E. Levy more than expected).

Fields of papers citing papers by Daniel E. Levy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel E. Levy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel E. Levy. The network helps show where Daniel E. Levy may publish in the future.

Co-authorship network of co-authors of Daniel E. Levy

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel E. Levy. A scholar is included among the top collaborators of Daniel E. Levy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel E. Levy. Daniel E. Levy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Levy, Daniel E., et al.. (2024). Differential effect by chronic disease risk: A secondary analysis of the ChooseWell 365 randomized controlled trial. Preventive Medicine Reports. 42. 102736–102736. 2 indexed citations
2.
Tan, Xuefei, Richland Tester, Gregory R. Luedtke, et al.. (2010). Design and synthesis of piperazine-indole p38α MAP kinase inhibitors with improved pharmacokinetic profiles. Bioorganic & Medicinal Chemistry Letters. 20(3). 828–831. 12 indexed citations
3.
Tester, Richland, Xuefei Tan, Gregory R. Luedtke, et al.. (2010). Amide-based inhibitors of p38α MAP kinase. Part 2: Design, synthesis and SAR of potent N-pyrimidyl amides. Bioorganic & Medicinal Chemistry Letters. 20(8). 2560–2563. 2 indexed citations
4.
Levy, Daniel E., et al.. (2010). PEGylated iminodiacetic acid zinc complex stabilizes cationic RNA-bearing nanoparticles. Bioorganic & Medicinal Chemistry Letters. 20(18). 5499–5501. 1 indexed citations
5.
Luedtke, Gregory R., Xuefei Tan, Richland Tester, et al.. (2010). Amide-based inhibitors of p38α MAP kinase. Part 1: Discovery of novel N-pyridyl amide lead molecules. Bioorganic & Medicinal Chemistry Letters. 20(8). 2556–2559. 10 indexed citations
6.
Levy, Daniel E., B.G. Frederick, Bing Luo, & Samuel Zalipsky. (2010). Heterobifunctional PEGs: Efficient synthetic strategies and useful conjugation methodologies. Bioorganic & Medicinal Chemistry Letters. 20(22). 6823–6826. 1 indexed citations
7.
Mavunkel, Babu, John Perumattam, Xuefei Tan, et al.. (2009). Piperidine-based heterocyclic oxalyl amides as potent p38α MAP kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 20(3). 1059–1062. 21 indexed citations
8.
Levy, Daniel E., Qing Lu, Zheng Chen, et al.. (2008). Aryl–indolyl maleimides as inhibitors of CaMKIIδ. Part 1: SAR of the aryl region. Bioorganic & Medicinal Chemistry Letters. 18(7). 2390–2394. 14 indexed citations
9.
Levy, Daniel E., Qing Lu, Zheng Chen, et al.. (2008). Aryl-indolyl maleimides as inhibitors of CaMKIIδ. Part 2: SAR of the amine tether. Bioorganic & Medicinal Chemistry Letters. 18(7). 2395–2398. 9 indexed citations
10.
Mavunkel, Babu, Yongjin Xu, Bindu Goyal, et al.. (2008). Pyrimidine-based inhibitors of CaMKIIδ. Bioorganic & Medicinal Chemistry Letters. 18(7). 2404–2408. 13 indexed citations
11.
Chen, Zheng, John Perumattam, Yongjin Xu, et al.. (2008). Aryl–indolyl maleimides as inhibitors of CaMKIIδ. Part 3: Importance of the indole orientation. Bioorganic & Medicinal Chemistry Letters. 18(7). 2399–2403. 6 indexed citations
12.
Levy, Daniel E.. (2008). Arrow Pushing in Organic Chemistry. 16 indexed citations
13.
Levy, Daniel E. & Péter Fügedi. (2005). Strategies towards C-Glycosides. ChemInform. 38(11). 293–372. 5 indexed citations
14.
Iwatsubo, Kousaku, Susumu Minamisawa, Takashi Tsunematsu, et al.. (2004). Direct Inhibition of Type 5 Adenylyl Cyclase Prevents Myocardial Apoptosis without Functional Deterioration. Journal of Biological Chemistry. 279(39). 40938–40945. 88 indexed citations
15.
Li, Chris, Warren J. Cantor, Nafiseh Nili, et al.. (2002). Arterial repair after stenting and the effects of gm6001, a matrix metalloproteinase inhibitor. Journal of the American College of Cardiology. 39(11). 1852–1858. 63 indexed citations
16.
Levy, Daniel E., Ming Bao, James Tomlinson, & Robert M. Scarborough. (2002). Hydroxamate based inhibitors of adenylyl cyclase. Part 2: The effect of cyclic linkers on P-site binding. Bioorganic & Medicinal Chemistry Letters. 12(21). 3089–3092. 8 indexed citations
17.
Levy, Daniel E., Charles K. Marlowe, Ming Bao, et al.. (2002). Hydroxamate based inhibitors of adenylyl cyclase. Part 1: The effect of acyclic linkers on P-site binding. Bioorganic & Medicinal Chemistry Letters. 12(21). 3085–3088. 8 indexed citations
18.
Mehta, Shamir R, Robert J. Chisholm, Ranga Robinson, et al.. (1996). Matrix metalloproteinase inhibition reduces collagen synthesis and content after arterial injury. Journal of the American College of Cardiology. 27(2). 290–290. 1 indexed citations
19.
Strauss, Bradley H., Ranga Robinson, Wayne Batchelor, et al.. (1996). In Vivo Collagen Turnover Following Experimental Balloon Angioplasty Injury and the Role of Matrix Metalloproteinases. Circulation Research. 79(3). 541–550. 138 indexed citations
20.
MUSSER, JOHN H., Mark Anderson, & Daniel E. Levy. (1995). Glycomimetics as Selectin Inhibitors. Current Pharmaceutical Design. 1(2). 221–232. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexander S. Antonov Breakdown of academic impact, for papers by Sonia Lamontagne Breakdown of academic impact, for papers by Robert A. Galemmo Breakdown of academic impact, for papers by Christopher R. Smith Breakdown of academic impact, for papers by Diane A. Trainor Breakdown of academic impact, for papers by Karl F. Erhard Breakdown of academic impact, for papers by Thais M. Sielecki Breakdown of academic impact, for papers by John Wityak Breakdown of academic impact, for papers by Patricia Kraft Breakdown of academic impact, for papers by Bernd Riedl
Rankless by CCL
2026